

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

**APPROVAL OF QUOTATION OF
JIANGSU BEST NEW MEDICAL ON THE NEEQ**

References are made to the announcements of SSY Group Limited (the “**Company**”) dated 28 January 2022, 13 December 2021 and 18 October 2021 (the “**Announcements**”) in relation to a possible spin-off and separate quotation of the shares of Jiangsu Best New Medical Material Co., Ltd.* (江蘇博生醫用新材料股份有限公司) (“**Jiangsu Best New Medical**”) on the National Equities Exchange and Quotations (the “**NEEQ**”). Capitalised terms used herein shall have the same meaning as those defined in the Announcements, unless the context requires otherwise.

The Company is pleased to announce that, on 28 April 2022, Jiangsu Best New Medical has received a letter of approval issued by the NEEQ Co., Ltd. approving the quotation of its shares on the NEEQ.

LISTING RULES IMPLICATIONS

The Possible Spin-off will involve the Placing of up to 15,000,000 new shares of Jiangsu Best New Medical (representing approximately 6.98% of the enlarged issued share capital of Jiangsu Best New Medical) in the PRC, which will constitute a deemed disposal by the Company of its interest in Jiangsu Best New Medical under Rule 14.29 of the Listing Rules.

As it is expected that all the applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Placing will be less than 5%, the Placing will not constitute a notifiable transaction under Chapter 14 of the Listing Rules and will not be subject to the requirements under paragraph 3(e) of Practice Note 15 and Chapter 14 of the Listing Rules.

As at the date of this announcement, the size and structure of the Placing and the subscribers' identities, have not yet been finalized. The Company will comply with any additional requirement under Chapters 14 and 14A of the Listing Rules (if applicable) and keep its shareholders and potential investors informed by making further announcement(s) in connection with the Possible Spin-off as and when appropriate in compliance with the Listing Rules.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company. Any person who is in doubt about his position or any action to be taken is recommended to consult his own professional adviser(s).

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 28 April 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

** for identification purpose only*